Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

F. Blandini, M. T. Armentero, R. Fancellu, E. Blaugrund, G. Nappi

Research output: Contribution to journalArticlepeer-review


Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-1- aminoindane] or saline (controls). Both doses of rasagiline markedly increased the survival of dopaminergic neurons in the lesioned substantia nigra, compared to controls (+97% and +119%, respectively). Treatment with the lower dose of rasagiline also abolished the motor stereotypies associated with nigrostriatal lesion. Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD).

Original languageEnglish
Pages (from-to)455-459
Number of pages5
JournalExperimental Neurology
Issue number2
Publication statusPublished - Jun 2004


  • 6-Hydroxydopamine
  • Striatum
  • Substantia nigra
  • Tyrosine hydroxylase

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)


Dive into the research topics of 'Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease'. Together they form a unique fingerprint.

Cite this